Literature DB >> 30229548

Inflammation and Prostate Cancer.

Ashutosh K Tewari1, Jennifer A Stockert2, Shalini S Yadav2, Kamlesh K Yadav2, Irtaza Khan2.   

Abstract

Chronic inflammation resulting from infections, altered metabolism, inflammatory diseases or other environmental factors can be a major contributor to the development of several types of cancer. In fact around 20% of all cancers are linked to some form of inflammation. Evidence gathered from genetic, epidemiological and molecular pathological studies suggest that inflammation plays a crucial role at various stages of prostatic carcinogenesis and tumor progression. These include initiation, promotion, malignant conversion, invasion, and metastasis. Detailed basic and clinical research in these areas, focused towards understanding the etiology of prostatic inflammation, as well as the exact roles that various signaling pathways play in promoting tumor growth, is critical for understanding this complex process. The information gained would be useful in developing novel therapeutic strategies such as molecular targeting of inflammatory mediators and immunotherapy-based approaches.

Entities:  

Keywords:  Adaptive immune system; Chemokines; Cytokines; Inflammation; Innate immune system; Lymphocytes; Macrophages; Oxidative stress; Prostate cancer

Mesh:

Year:  2018        PMID: 30229548     DOI: 10.1007/978-3-319-95693-0_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

1.  Exposure to an environmentally relevant phthalate mixture during prostate development induces microRNA upregulation and transcriptome modulation in rats.

Authors:  Wellerson R Scarano; Amina Bedrat; Luiz G Alonso-Costa; Ariana M Aquino; Bruno Fantinatti; Luis A Justulin; Luis F Barbisan; Paula P Freire; Jodi A Flaws; Lemos Bernardo
Journal:  Toxicol Sci       Date:  2019-06-14       Impact factor: 4.849

2.  Dietary Pterostilbene for MTA1-Targeted Interception in High-Risk Premalignant Prostate Cancer.

Authors:  Rutu Hemani; Ishani Patel; Ninad Inamdar; Gisella Campanelli; Virginia Donovan; Avinash Kumar; Anait S Levenson
Journal:  Cancer Prev Res (Phila)       Date:  2021-10-21

3.  Oncogenic ACSM1 in prostate cancer is through metabolic and extracellular matrix-receptor interaction signaling pathways.

Authors:  Yongchen Guo; Chunna Ren; Wentao Huang; Wancai Yang; Yonghua Bao
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

4.  Alternol triggers immunogenic cell death via reactive oxygen species generation.

Authors:  Changlin Li; Ying Zhang; Siyuan Yan; Guoan Zhang; Wei Wei; Zhi Qi; Benyi Li
Journal:  Oncoimmunology       Date:  2021-07-21       Impact factor: 8.110

5.  Pre-treatment red blood cell distribution width as a predictor of clinically significant prostate cancer.

Authors:  Tian-Bao Huang; Liang-Yong Zhu; Guang-Chen Zhou; Xue-Fei Ding
Journal:  Int Urol Nephrol       Date:  2021-05-28       Impact factor: 2.370

Review 6.  Systemic Effects Reflected in Specific Biomarker Patterns Are Instrumental for the Paradigm Change in Prostate Cancer Management: A Strategic Paper.

Authors:  Olga Golubnitschaja; Peter Kubatka; Alena Mazurakova; Marek Samec; Abdullah Alajati; Frank A Giordano; Vincenzo Costigliola; Jörg Ellinger; Manuel Ritter
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

Review 7.  Advances in research on the interaction between inflammation and cancer.

Authors:  Xin-Da Song; Ya-Ni Wang; Ai-Li Zhang; Bin Liu
Journal:  J Int Med Res       Date:  2019-12-29       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.